High VEGFA Expression Is Associated with Improved Progression-Free Survival after Bevacizumab Treatment in Recurrent Glioblastoma

High VEGFA Expression Is Associated with Improved Progression-Free Survival after Bevacizumab Treatment in Recurrent Glioblastoma

Glioblastoma (GB) is one of the deadliest human cancers. Many GB patients do not respond to treatment, and inevitably die within a median of 15–18 months post-diagnosis, highlighting the need for reliable biomarkers to aid clinical management and treatment evaluation. The GB microenvironment holds t...

Full description

Bibliographic Details
Main Authors: Bárbara Alves, Joana Peixoto, Sofia Macedo, Jorge Pinheiro, Bruno Carvalho, Paula Soares, Jorge Lima, Raquel T. Lima
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:Cancers
Subjects:
glioblastoma
secretome
biomarkers
immunohistochemistry
VEGFA
YKL40
Online Access:https://www.mdpi.com/2072-6694/15/8/2196

Similar Items

Similar Items